Gilead Sciences to Release 4th-Quarter Earnings

GuruFocus.com
0

- By Alberto Abaterusso

It is time for Gilead Sciences, Inc. (GILD) to announce its earnings for the fourth quarter of fiscal 2017.

The California-based U.S. biopharmaceutical company will inform the market about earnings for the last three months of 2017 on Tuesday after the Nasdaq stock exchange closes.

Twenty-two analysts were surveyed on Gilead Sciences' earnings for the quarter. Their estimates range between a low of $1.29 per share and a high of $2.


Source: Yahoo Finance

The average forecast says the healthcare company will report net earnings of $1.67 per share, a 38.1% decline from the same quarter last year.

Analysts were also surveyed on the top line of Gilead Sciences' income statement for the last quarter of 2017 and for the entire year. The chart also illustrates estimates on Gilead Sciences' revenues for the reporting periods.

Source: Yahoo Finance

For the quarter that ended Dec. 30, 2017, 21 estimates have produced a mean of $5.73 billion. If the company has met its forecast, Gilead Sciences will disclose a revenue of $25.83 billion for twelve months of fiscal 2017, which represents a 15% decline from 2016.

The chart below shows the trend in Gilead Sciences' total revenues over the last five fiscal years:

Tuesday, the company will also update the shareholders on the company's balance sheet figures for the periods in question.

GuruFocus assigns Gilead Sciences a financial strength rating of 6 of 10. The rating has been built based on several financial ratios using most recent quarter balance sheet figures and trailing 12 months numbers of the company's income statement.

Gilead Sciences is trading at $81.73 per share, about $7.8 below the 52-week high of $89.54 per share. The stock has a 52-week low of $63.76 per share and a market capitalization of $106.761 billion.

For the 52 weeks through Feb. 1, Gilead Sciences has gained 0.69% emulating the NASDAQ Biotechnology Index (NBI). The healthcare stock was outperformed by the NASDAQ-100 (^NDX) by 10.3% and by the S&P 500 index by 7.5%.

Source: Yahoo Finance

Gilead Sciences has a price-book (P/B) ratio of 4.30 versus an industry average of 4.10 and a price-sales (P/S) ratio of 3.93 times versus an industry median of 11.76 times.

The chart of Peter Lynch, which is powered by GuruFocus, indicates the share price is far below both the earnings line (P/E=15) and the price at med P/E without NRI (P/E=21.4):

Gilead Sciences has a forward dividend of $2.08 and a forward yield of 2.49%.

The current dividend yield is 2.54% versus a S&P 500 current dividend yield of 1.77%.

(Disclosure:I have no positions in any security mentioned in this article.)

This article first appeared on GuruFocus.


Advertisement

Recommended Stories